X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (568) 568
Newspaper Article (13) 13
Patent (11) 11
Book Chapter (4) 4
Book / eBook (1) 1
Magazine Article (1) 1
Publication (1) 1
Video Recording (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (225) 225
melanoma (155) 155
oncology (142) 142
male (119) 119
female (109) 109
middle aged (99) 99
melanoma - drug therapy (95) 95
aged (88) 88
dermatology (79) 79
skin neoplasms - drug therapy (79) 79
adult (76) 76
skin neoplasms - pathology (75) 75
melanoma - pathology (65) 65
metastasis (65) 65
cancer (57) 57
antineoplastic agents - therapeutic use (55) 55
treatment outcome (54) 54
aged, 80 and over (47) 47
metastatic melanoma (46) 46
survival (44) 44
cutaneous melanoma (42) 42
neoplasm staging (42) 42
care and treatment (41) 41
immunotherapy (40) 40
metastases (39) 39
ipilimumab (37) 37
skin neoplasms - therapy (37) 37
melanoma - secondary (36) 36
skin cancer (36) 36
mutation (35) 35
antineoplastic agents - adverse effects (34) 34
disease-free survival (34) 34
skin neoplasms - diagnosis (34) 34
analysis (32) 32
clinical trials (32) 32
melanoma - therapy (32) 32
prognosis (32) 32
melanoma - mortality (31) 31
patients (30) 30
chemotherapy (28) 28
high-risk melanoma (28) 28
malignant-melanoma (28) 28
melanoma - genetics (28) 28
therapy (28) 28
germany (27) 27
vemurafenib (27) 27
hematology, oncology and palliative medicine (26) 26
skin (26) 26
abridged index medicus (25) 25
proto-oncogene proteins b-raf - genetics (25) 25
follow-up studies (24) 24
medicine, general & internal (24) 24
tumors (24) 24
melanoma - diagnosis (23) 23
medicine, research & experimental (22) 22
risk factors (22) 22
skin neoplasms - mortality (21) 21
adjuvant therapy (20) 20
antineoplastic combined chemotherapy protocols - therapeutic use (20) 20
diagnosis (20) 20
surgery (20) 20
trial (20) 20
young adult (20) 20
antibodies, monoclonal - therapeutic use (19) 19
chemotherapy, adjuvant (19) 19
dacarbazine (19) 19
research (19) 19
adolescent (18) 18
antineoplastic agents - administration & dosage (18) 18
melanoma - surgery (18) 18
skin neoplasms - surgery (18) 18
disease progression (17) 17
kaplan-meier estimate (17) 17
survival analysis (17) 17
antibodies, monoclonal - adverse effects (16) 16
interferon (16) 16
practice guidelines as topic (16) 16
proto-oncogene proteins b-raf - antagonists & inhibitors (16) 16
dabrafenib (15) 15
medicine & public health (15) 15
skin neoplasms - genetics (15) 15
american joint committee (14) 14
drug therapy (14) 14
efficacy (14) 14
interferon-alpha (14) 14
interferon-alpha - therapeutic use (14) 14
open-label (14) 14
patient outcomes (14) 14
time factors (14) 14
braf (13) 13
dosage and administration (13) 13
drug administration schedule (13) 13
medical prognosis (13) 13
phase-ii (13) 13
quality of life (13) 13
studies (13) 13
basal cell carcinoma (12) 12
carcinoma, basal cell - drug therapy (12) 12
combination (12) 12
complications and side effects (12) 12
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Best practice onkologie, ISSN 0946-4565, 06/2017, Volume 12, Issue 3-4, pp. 164 - 167
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2011, Volume 364, Issue 26, pp. 2517 - 2526
Journal Article
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2012, Volume 30, Issue 21, pp. 2691 - 2697
Monoclonal antibodies directed against the immune checkpoint protein cytotoxic T-lymphocyte antigen-4 (CTLA-4; CD152)-ipilimumab and tremelimumab-have been... 
REGRESSION | METASTATIC MELANOMA | LYMPHOCYTE-ASSOCIATED ANTIGEN-4 | EFFICACY | ONCOLOGY | PHASE-II | MONOCLONAL-ANTIBODY | CTLA-4 | PATIENT | CANCER-IMMUNOTHERAPY | BLOCKADE | Stevens-Johnson Syndrome - immunology | Peripheral Nervous System Diseases - chemically induced | Skin Neoplasms - drug therapy | Humans | Ipilimumab | Antibodies, Monoclonal - adverse effects | Scleritis - chemically induced | Antineoplastic Agents - administration & dosage | Liver - immunology | Liver - drug effects | Antineoplastic Agents - adverse effects | Diarrhea - immunology | Pancreatitis - immunology | Scleritis - immunology | Mucous Membrane - drug effects | Colitis - immunology | Peripheral Nervous System Diseases - immunology | Antibodies, Monoclonal - immunology | Drug Eruptions - immunology | Skin - immunology | Melanoma - metabolism | Skin Neoplasms - pathology | Skin Neoplasms - immunology | Antineoplastic Agents - immunology | CTLA-4 Antigen - drug effects | Lymphatic Diseases - immunology | Antibodies, Monoclonal - pharmacokinetics | CTLA-4 Antigen - immunology | Pancreatitis - chemically induced | Melanoma - secondary | Chemical and Drug Induced Liver Injury - immunology | Pituitary Gland - immunology | Skin Neoplasms - metabolism | Lymphatic Diseases - chemically induced | Mucous Membrane - immunology | Antibodies, Monoclonal - administration & dosage | Melanoma - immunology | Uveitis - immunology | Melanoma - drug therapy | Uveitis - chemically induced | Pituitary Gland - drug effects | Skin - drug effects | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2015, Volume 386, Issue 9992, pp. 444 - 451
Journal Article
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 3, pp. 323 - 332
Summary Background In the BRIM-3 trial, vemurafenib was associated with risk reduction versus dacarbazine of both death and progression in patients with... 
Hematology, Oncology and Palliative Medicine
Journal Article
Journal Article
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 19, pp. 1813 - 1823
In patients with surgically resected melanoma, those with BRAF mutations who received 1 year of oral adjuvant therapy with dabrafenib and trametinib had a 53%... 
HIGH-RISK MELANOMA | SURVIVAL | MEDICINE, GENERAL & INTERNAL | INTERFERON-ALPHA-2B | PLACEBO | THERAPY | MEK INHIBITION | PHASE-III | DOUBLE-BLIND | HAZARD | IPILIMUMAB | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Oximes - therapeutic use | Male | Adjuvants, Immunologic - adverse effects | Young Adult | Melanoma - genetics | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Imidazoles - therapeutic use | Adjuvants, Immunologic - therapeutic use | Skin Neoplasms - surgery | Double-Blind Method | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Neoplasm Recurrence, Local | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Adolescent | Survival Analysis | Aged | Pyridones - therapeutic use | Melanoma - surgery | Mutation | Neoplasm Staging | Pyridones - adverse effects | Melanoma - mortality | Usage | Relapse | Patient outcomes | Analysis | Melanoma | Adjuvant treatment | Outcome and process assessment (Health Care) | Reports | Drug therapy | Cancer | Diseases | Medical imaging | Oncology | Metastasis | FDA approval | Kinases | Cancer therapies | Survival | Skin cancer | Metastases | Medical prognosis | Immunotherapy | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article